Bilastine is a new antihistamine using in the treatment of allergic rhinitis
- Authors: Krivopalov A.A1, Konoplev O.I1, Shervashidze S.V1, Shatalov V.A1
-
Affiliations:
- Saint Petersburg Research Institute of Ear, Nose, Throat and Speech of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 3 (2017)
- Pages: 87-90
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/94843
- ID: 94843
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A. A Krivopalov
Saint Petersburg Research Institute of Ear, Nose, Throat and Speech of the Ministry of Health of the Russian Federation
Email: krivopalоv@list.ru
канд. мед. наук, ст. науч. сотр. ФГБУ СПб «НИИ уха, горла, носа и речи» 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaya, d. 9
O. I Konoplev
Saint Petersburg Research Institute of Ear, Nose, Throat and Speech of the Ministry of Health of the Russian Federation
Email: oikonoplev@mail.ru
д-р мед. наук, проф., зам. дир. по клинической работе ФГБУ СПб «НИИ уха, горла, носа и речи» 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaya, d. 9
S. V Shervashidze
Saint Petersburg Research Institute of Ear, Nose, Throat and Speech of the Ministry of Health of the Russian Federation
Email: shesophia@yandex.ru
врач-оториноларинголог ФГБУ СПб «НИИ уха, горла, носа и речи» 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaya, d. 9
V. A Shatalov
Saint Petersburg Research Institute of Ear, Nose, Throat and Speech of the Ministry of Health of the Russian Federation
Email: mdshateau@yandex.ru
врач-оториноларинголог ФГБУ СПб «НИИ уха, горла, носа и речи» 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaya, d. 9
References
- Lucero M.L, Gonzalo A, Mumford R et al. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol 2012; 35 (Suppl. l): 18-24.
- Bousquet J, Khaltaev N, Cruz A.A et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8-160.
- Василевский И.В. Реабилитация детей и подростков с заболеваниями органов дыхания, пищеварения, почек, сердечно - сосудистой системы и аллергическими болезнями в условиях поликлиники. Минск: БелМАПО, 2007: с. 157-71.
- Горячкина Л.А., Кашкин Е.П., Терехова Е.П. и др. Клиническая аллергология и иммунология: руководство для практикующих врачей. Под ред. Л.А.Горячкиной и Е.П.Кашкина. М.: Миклош, 2009.
- Graff C, Struijk J.J, Kanters J.K et al. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double - blind, placebo - controlled, thorough QTc study. Clin Drug Invest 2012; 32: 339-51.
- Feldberg W, Kellaway C.H. Liberation of histamine and formation of lysocithin - like substances by cobra venom. J Physiol 1988; 94: 187-91.
- Kellaway C.H, Trethewie E.R. The liberation of a slow - reacting smooth muscle - stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30: 121-45.
- Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416-35.
- Sadaba B, Gomez-Guiu A, Azanza J.R et al. Oral availability of bilastine. Clin Drug Invest 2013; 33: 375-81.
- Church M.K. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Exp Opin Drug Saf 2011; 10 (5): 779-93.
- Corcostegui R, Labeaga L, Innerarity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D 2006; 7: 219-31.
- Sastre J, Mullol J, Valero A. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121-30.
- Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi - centre, double - blind, randomized, placebo - controlled study. Allergy 2010; 65: 516-28.
- Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy 2014; 4: 142-8.
- Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine HI-receptor occupancy using 1 lC-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890-900.
- Dykewicz M.S, Fineman S, Skoner D.P. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478-518.
Supplementary files
